140
Participants
Start Date
February 29, 2012
Primary Completion Date
February 1, 2023
Study Completion Date
December 31, 2025
HKI-272
240 mg orally, once daily
Surgical Resection
Neratinib concentrations from craniotomy specimen, CSF, plasma Neratinib.
Capecitabine
750 mg/m2 orally, twice daily (1,500 mg/m2 daily) for 14 days followed by 7 days off
HKI-272
160 mg orally, once daily
Ado-Trastuzumab Emtansine
3.6 mg/kg IV every 3 weeks
UPMC Cancer Centers - Magee-Womens Hospital of UPMC, Pittsburgh
UPMC Hillman Cancer Center, Pittsburgh
Arnold Palmer Cancer Center-Greensburg, Greensburg
UPMC Passavant Cranberry, Cranberry Township
UPMC Ortenzio Cancer Center, Mechanicsburg
UPMC Pinnacle Harrisburg, Harrisburg
MedStar Georgetown Univeristy Hospital, Washington D.C.
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore
University of North Carolina at Chapel Hill - Lineberger Comprehensive Cancer Center, Chapel Hill
Duke University Medical Center, Durham
University of Michigan Comprehensive Cancer Center, Ann Arbor
Mayo Clinic, Rochester
Baylor College of Medicine Lester and Sue Smith Breast Center, Houston
MD Anderson Cancer Center, Houston
University of California, San Francisco Medical Center, San Francisco
Beth Israel Deaconess Medical Center, Boston
Dana-Farber Cancer Institute, Boston
Massachusetts General Hosptial, Boston
Translational Breast Cancer Research Consortium
OTHER
Puma Biotechnology, Inc.
INDUSTRY
Dana-Farber Cancer Institute
OTHER